US 11,833,154 B2
Methods of treatment of myeloproliferative neoplasm
Ross L. Levine, New York, NY (US); and Anna Sophia McKenney, Selkirk, NY (US)
Assigned to Memorial Sloan Kettering Cancer Center, New York, NY (US)
Filed by Memorial Sloan Kettering Cancer Center, New York, NY (US)
Filed on Dec. 16, 2021, as Appl. No. 17/553,588.
Application 17/553,588 is a division of application No. 16/615,115, granted, now 11,229,653, previously published as PCT/US2018/031090, filed on May 4, 2018.
Claims priority of provisional application 62/535,146, filed on Jul. 20, 2017.
Claims priority of provisional application 62/502,456, filed on May 5, 2017.
Prior Publication US 2022/0105097 A1, Apr. 7, 2022
Int. Cl. A61K 31/53 (2006.01); A61P 35/00 (2006.01); A61K 31/519 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/53 (2013.01) [A61K 31/519 (2013.01); A61P 35/00 (2018.01); A61K 9/0053 (2013.01)] 20 Claims
 
1. A method of treating a myeloproliferative neoplasm or acute myeloid leukemia in a subject comprising administering to the subject a combination of a therapeutically effective amount of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol having the following formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, solvate, tautomer, stereoisomer, isotopologue, prodrug, metabolite, or a polymorph thereof (COMPOUND 1) and a therapeutically effective amount of a JAK2 inhibitor selected from TG101348, CYT387, lestaurtinib, AZD1480, pacritinib, XL019, NCB0-16562, NVP-BSK805, R723, hydroxycarbamide, SAR302503, tasocitinib and INCB16562, wherein the subject harbors a mutant allele of IDH2 and a mutant allele of JAK2.